---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Dosage forms and strengths"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Dosage forms and strengths. Topics: Investigational dosage form: 400 mg film-coated immediate-release tablet, Tablets per daily dose in NATiV3: two or three 400 mg tablets, Tablets per daily dose in LEGEND: two 400 mg tablets, Packaging of the investigational tablets: HDPE bottles, and 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/dosage-forms-and-strengths"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Dosage forms and strengths

<a id="heading-2.1.2.2"></a>

## 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

### Investigational dosage form: 400 mg film-coated immediate-release tablet

> “The Investigational Medicinal Product is a white to off-white bi-convex tablet, weighing approximately 927 mg and showing a breakline to facilitate the administration to patients.”
> “The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation.”
> “Each active tablet contains 400 mg of the active substance lanifibranor in an immediate release formulation.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-2.1.2.2-2"></a>

### Tablets per daily dose in NATiV3: two or three 400 mg tablets

> “2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food”
> “3 Lanifibranor tablets 400mg with food”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-2.1.2.2-3"></a>

### Tablets per daily dose in LEGEND: two 400 mg tablets

> “Tablets of lanifibranor 400 mg, administered on a daily dose of 800 mg lanifibranor or placebo, i.e., 2 tablets of 400 mg/placebo orally once daily (QD) during breakfast, for a total of 24 weeks”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.2-4"></a>

### Packaging of the investigational tablets: HDPE bottles

> “The lanifibranor tablets and PTM are packaged into High-density polyethylene (HDPE) bottles of 100 ml (38 tablets for a treatment period of one month, plus a use margin of 1 week) with proper closures fitted with a silicagel cartridge.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “Two bottles of 30 tablets are placed into a carton to get a 4-weeks kit (see Figure 2).”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.2-5"></a>

### Storage and stability of the investigational tablets

> “Based on the results of the ongoing stability studies, a shelf life of 2 years (storage at 25°C or below) is proposed for the Investigational Medicinal Product provided it is stored in the original package, the HDPE bottles.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

> “The IMP should be stored at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). It should be stored in the original containers (i.e., bottles).”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-2.1.2.2-6"></a>

### Bioequivalence study in healthy volunteers, France, February to May 2026

> “A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor”

Source: [EU Clinical Trials Information System 2025-524385-18-00](https://euclinicaltrials.eu/ctis-public/view/2025-524385-18-00)

<a id="topic-2.1.2.2-7"></a>

### Commercial strengths and package sizes

No evidence found.

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
